A trial for a dengue vaccine has been carried out successfully for the first time in Bangladesh.
Researchers at the International Centre for Diarrhoeal Disease Research (icddr,b) and Vermont University's Larner College of Medicine in the US successfully completed these tests, the icddr,b said on Thursday.
The international journal Lancet published the result of the clinical trial along with the study.
This vaccine has been named TV-005 (Tetravelent).
Experimental application of the vaccine has shown that it is effective against all four existing types of dengue virus – Den-1, Den-2, Den-3 and Den-4.
A single dose of this vaccine can protect against dengue.
However, more research is needed on this vaccine, the researchers said.
The second phase of the trial or test was done in Bangladesh.
The vaccine has completed 42 different phases of trials in various countries around the world. Notably, the third phase of the trial was carried out in India.
